Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?
| Autor: | Asher Chanan-Khan, Kirtipal Bhatia, Sikander Ailawadhi, Sonikpreet Aulakh, Zahara Meghji |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
medicine.medical_specialty Ethnic group Affect (psychology) Health Services Accessibility 03 medical and health sciences 0302 clinical medicine Outcome Assessment Health Care Health care Humans Medicine Healthcare Disparities Intensive care medicine Location Socioeconomic status Multiple myeloma Aged Equity (economics) business.industry Age Factors Hematology Middle Aged medicine.disease Disadvantaged Oncology 030220 oncology & carcinogenesis Medical emergency Multiple Myeloma business Delivery of Health Care 030215 immunology |
| Zdroj: | Current Hematologic Malignancy Reports. 12:309-316 |
| ISSN: | 1558-822X 1558-8211 |
| Popis: | Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink